Clinical Takeaway
People with PTSD and co-occurring substance use disorders who also use cannabis can still benefit meaningfully from trauma-focused treatments. Clinicians should not withhold or delay evidence-based PTSD care based on a patient’s cannabis use status.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis addresses a critical clinical gap by examining whether evidence-based trauma-focused treatments remain efficacious in patients with co-occurring PTSD and cannabis use, a population frequently excluded from efficacy trials and presenting major treatment challenges in routine practice. The findings have direct implications for treatment selection and patient counseling, as they clarify whether cannabis use should alter treatment approaches or expectations for PTSD+SUD populations. Understanding these efficacy differentials can optimize resource allocation and improve outcomes in the substantial proportion of trauma-exposed individuals who present with polysubstance use patterns.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this individual patient meta-analysis from Project Harmony offers valuable real-world insights into how cannabis use affects trauma-focused treatment outcomes in people with comorbid PTSD and substance use disorders, several important limitations warrant careful interpretation. The analysis draws from a subset of only four RCTs embedded within a larger 36-trial dataset, which may limit statistical power and generalizability compared to the full cohort, and the meta-analytic approach cannot fully account for unmeasured confounders such as cannabis potency, frequency of use, timing relative to treatment, or whether cannabis served primarily as self-medication versus independent substance use. Additionally, the heterogeneity of trauma-focused treatments and baseline PTSD/SUD presentations across studies, combined with varying definitions and measurement of cannabis use, creates substantial clinical complexity that aggregate analyses may obscure. Clinically, these findings should prompt individualized assessment of cannabis use patterns during PTSD treatment rather than categorical exclusion, while recognizing that active cannabis use may complicate engagement with